We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
After a sharp market downturn in the previous two years, the biotech industry started to surge in 2003, driven in part by a critical mass of biological drugs on the market and many experimental products on the verge of gaining FDA approval, a new study finds.
Although only two states so far allow psychologists with training in psychopharmacology to prescribe mental health drugs — making them attractive pharma marketing targets — the American Psychological Association (APA) is trying to “get ahead of the curve” in developing professional standards for relationships with drugmakers, according to a senior APA official.
A Minnesota state court has ordered GlaxoSmithKline (GSK) to provide the state’s attorney general access to documents related to GSK’s efforts to limit sales of its drugs to Canadian pharmacies that sell the drug products back to consumers in the U.S.
Generic firms are expected to post strong growth for the rest of the year, says a pharmaceutical analyst who also warns that next year could be tougher on firms’ bottom lines.
Louisiana last week became the second state in the U.S. to allow psychologists to write prescriptions, creating a potential new marketing front for manufacturers of mental health drugs.
Boston Scientific revealed late last week that it intends to make slight alterations to its high-profile Taxus drug-eluting stent system to address reports that surgeons have had difficulty withdrawing balloons used to place the devices in patients.
Higher average clinical research and development (R&D) costs for drugs in some therapeutic classes are helping create an incentive for drugmakers to shift their efforts among disease states, according to a new study by the Tufts Center for the Study of Drug Development (CSDD).
Generic drugmaker Ivax has shipped the first generic version of Bristol-Myers Squibb’s (BMS’) Type 2 diabetes drug Glucovance (glyburide/metformin HCl) tablets, a move that triggered the launch of BMS’ authorized generic product distributed by Par Pharmaceutical.